Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:41am, Friday, 21'st Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
08:52am, Friday, 21'st Nov 2025
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a par
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
08:48am, Friday, 21'st Nov 2025
GSK plc (NYSE: GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court.
GSK, AnaptysBio Sue Each Other Over Cancer Drug License
06:14am, Friday, 21'st Nov 2025
The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of endometrial cancer.
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
03:50am, Friday, 21'st Nov 2025
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a
FTSE 100 Live: Stocks to plunge after wild ride on Wall Street, as bitcoin tumbles
02:54am, Friday, 21'st Nov 2025
7.54am: GSK steps up US dispute GSK PLC (LSE:GSK, NYSE:GSK) has stepped up a dispute over rights to its fast-growing cancer drug Jemperli in the US courts....
GSK unit sues AnaptysBio in row over Jemperli rights
02:36am, Friday, 21'st Nov 2025
GSK PLC (LSE:GSK, NYSE:GSK) has stepped up a dispute over rights to its fast-growing cancer drug Jemperli by having its US subsidiary Tesaro sue AnaptysBio in the Delaware Court of Chancery. Tesaro i
GSK unit sues AnaptysBio in row over Jemperli rights
02:32am, Friday, 21'st Nov 2025
GSK PLC (LSE:GSK, NYSE:GSK) has stepped up a dispute over rights to its fast-growing cancer drug Jemperli by having its US subsidiary Tesaro sue AnaptysBio...
GSK plc (GSK) Presents at Jefferies London Healthcare Conference 2025 Transcript
11:23am, Wednesday, 19'th Nov 2025
GSK plc ( GSK ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:30 AM EST Company Participants Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants Michael
GSK (GSK) is a Top-Ranked Momentum Stock: Should You Buy?
10:51am, Monday, 17'th Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Best Healthcare Stock to Hold in Uncertain Times
06:50am, Friday, 14'th Nov 2025
GlaxoSmithKline is now known simply as GSK. GSK stock trades for 13 times earnings and barely 11 times free cash flow.
Why GSK (GSK) is a Top Growth Stock for the Long-Term
10:46am, Thursday, 13'th Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact
12:00pm, Wednesday, 12'th Nov 2025
Exploring Kahn Brothers (Trades, Portfolio)' Recent 13F Filing and Investment Strategies Kahn Brothers (Trades, Portfolio) recently submitted their 13F filing
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
07:00am, Monday, 10'th Nov 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announce
Diageo considers external candidates for CEO role, including outgoing GSK boss, FT reports
01:39am, Saturday, 08'th Nov 2025
Diageo , the world's top spirits maker, has considered external candidates to be its chief executive, including outgoing GSK CEO Emma Walmsley, the Financial Times reported on Saturday, citing people
